Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic study of amrubicin in lung cancer patients with impaired hepatic function
jRCT1080221990
- Sponsor
- Sumitomo Pharma
- Start
- Dec 2012
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of amrubicin in small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), sponsored by Sumitomo Pharma. Primary endpoint: Pharmacokinetic parameters of amrubicin and/or its metabolites.
02
Drugs
amrubicin
03
Conditions
small cell lung cancer (SCLC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT1080221990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080221990.